T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen

Journal of Infectious Diseases

Volumn 191, Issue 7, 2005, Pages 1155-1163

  Lalezari, Jacob P ^a   Bellos, Nicholaos C ^b   Sathasivam, Kunthavi ^c   Richmond, Gary J ^d   Cohen, Calvin J ^e   Myers Jr , Robert A ^f   Henry, David H ^g   Raskino, Claire ⁱ   Melby, Tom ^h   Murchison, Hugh ^h   Zhang, Ying ^h   Spence, Rebecca ^h   Greenberg, Michael L ^h   DeMasi, Ralph A ^h   Miralles, G Diego ^h,j  

^a Quest Clinical Research   (United States)

^b South West Infectious Diseases ^*  (United States)

^c Elizabeth Taylor Medical Center   (United States)

^d North Broward Hospital District   (United States)

^e Boston Community Research Initiative of New England   (United States)

^f Phoenix Body Positive   (United States)

^g Pennsylvania Oncology Hematology Associates   (United States)

^h Trimeris Pharmaceuticals   (United States)

ⁱ ROCHE PRODUCTS LTD   (United Kingdom)

^j Trimeris Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; GLYCOPROTEIN GP 160; T 1249; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CRYSTALLOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; ECCHYMOSIS; ERYTHEMA; FATIGUE; FEMALE; FEVER; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PRURITUS; RASH; SKIN INDURATION; SKIN NODULE; THROMBOCYTOPENIA; TREATMENT FAILURE; VIREMIA; VIRUS ENVELOPE; VIRUS REPLICATION;

ADULT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; PEPTIDE FRAGMENTS; PHENOTYPE; PREGNANCY; RNA, VIRAL; TREATMENT FAILURE;

EID: 20144386372     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/427993     Document Type: Article

References (21)

1. LaBranche C, Galasso G, Moore JP, et al. HIV fusion and its inhibition. Antiviral Res 2001; 50:95-115.
2. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-85.
3. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-95.
4. Trottier B, Arastéh K, Henry K, et al. Durability of response to enfuvirtide through 48 weeks in the TORO trials (abstract H835]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: American Society of Microbiology, 2003.
5. Katlama C, Dominguez S, Duvivier C, et al. Long-term benefit of treatment interruption in salvage therapy (GIGHAART ANRS 097) [abstract 68]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston: Foundation of Retrovirology and Human Health, 2003.
6. Wei X, Decker JM, Liu H, et al. Emergence of resistant HIV-1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-905.
7. Sista P, Melby T, Greenberg ML, et al. Characterization of baseline and treatment-emergent resistance to T-20 (enfuvirtide) observed in phase II clinical trials: substitutions in gp41 amino acids 36-45 and enfuvirtide susceptibility of virus isolates. Antivir Ther 2002;7(Suppl 1):S56.
8. Greenberg ML, Melby T, Sista P, et al. Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks (abstract 41]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston: Foundation of Retrovirology and Human Health, 2003.
9. Eron J, Gulick R, Bartlett J, et al. Short-term safety and antiviral activity of T-1249, a second generation fusion inhibitor. J Infect Dis 2004; 189: 1075-83.
10. Menzo S, Castagna A, Monachetti A, et al. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 2004; 48:3253-9.
11. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89:263-73.
12. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387:426-30.
13. Whitcomb JM, Huang W, Fransen S, et al. Analysis of baseline enfuvirtide (T-20) susceptibility and co-receptor tropism in two phase III study populations [abstract 557]. In: Programs and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston: Foundation of Retrovirology and Human Health, 2003.
14. Hahn GJ, Meeker WQ. Statistical intervals: a guide for practitioners. New York: John Wiley & Sons, 1991.
15. Fagot JP, Mockenhaupt M, Bouwes-Bavinck J-N, for the EuroSCAR study group. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 15:1843-8.
16. Bourezane Y, Salard D, Hoen B, et al. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis 1998; 27:1321-2.
17. Bossi P, Colin D, Bricaire F, Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis 2000; 30:227-8.
18. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex difference in nevirapine rash. Clin Infect Dis 2001; 32:124-9.
19. Pirmohamed M, Park BK. HIV and drug allergy. Curr Opin Allergy Clin Immunol 2001; 1:311-6.
20. Campo RE, Rosa I, Lichtenberger PN, et al. Effect of class-specific therapy interruption on persistence of HIV type 1 antiretroviral resistance. AIDS Res Hum Retroviruses 2003; 19:653-6.
21. Jiang H, Decks SG, Kuritzkes DR, et al. Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis 2003; 188:1001-8.